Microbiology: Current Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Microbiology: Current Research (2024) Volume 8, Issue 5

Vaccine Development in Virology: From Traditional Methods to mRNA Technology.

Rakesh Verma*

Indian Institute of Microbial Research, India

*Corresponding Author:
Rakesh Verma
Indian Institute of Microbial Research, India
E-mail: ombamalu@uwc.ac.za

Received: 10-Oct-2024, Manuscript No. AAMCR-24-155086; Editor assigned: 11-Oct-2024, PreQC No. AAMCR-24-155086 (PQ); Reviewed: 22-Oct-2024, QC No. AAMCR-24-155086; Revised: 24-Oct-2024, Manuscript No. AAMCR-24-155086 (R); Published: 31-Oct-2024, DOI: 10.35841/aamcr-8.5.228

Citation: Verma R. Vaccine Development in Virology: From Traditional Methods to mRNA Technology. J Micro Bio Curr Res. 2024;8(5):228

Visit for more related articles at Microbiology: Current Research

Introduction

Vaccine development has played a critical role in protecting humanity from viral diseases, helping eradicate deadly infections such as smallpox and significantly reducing the impact of others like polio and measles. Over time, the process of vaccine development has evolved, from traditional methods involving weakened or inactivated viruses to the revolutionary mRNA technology used during the COVID-19 pandemic. This article explores the journey of vaccine development in virology, the mechanisms behind different approaches, and the promise of emerging technologies [1].

Vaccines are biological preparations that provide immunity to viral infections by stimulating the body's immune system to recognize and fight pathogens. They work by introducing antigens — components of the virus that trigger immune responses — into the body without causing illness. This trains the immune system to recognize the virus if it is encountered later, preventing infection or reducing its severity. The success of vaccines in combating viruses like smallpox, measles, and hepatitis B has made them one of the most effective tools in public health [2].

One of the earliest methods of vaccine development involves using live attenuated viruses. These are viruses that have been weakened so they do not cause disease but are still able to replicate in the host. Live attenuated vaccines, such as those for measles, mumps, and rubella (MMR), typically induce strong, long-lasting immune responses because they closely mimic natural infection. However, these vaccines carry risks, especially for individuals with weakened immune systems, as the weakened virus may still cause disease in some cases [3].

Another traditional approach involves inactivated virus vaccines, where the virus is killed using heat, chemicals, or radiation. The inactivated virus cannot replicate but can still trigger an immune response. Vaccines for polio, hepatitis A, and rabies are examples of this approach. While inactivated vaccines are safer for immunocompromised individuals, they often require multiple doses or booster shots to maintain immunity, as they do not provoke as strong or long-lasting a response as live attenuated vaccines [4].

Subunit vaccines represent a more targeted approach, containing only specific parts of the virus, such as proteins or glycoproteins, rather than the whole virus. The hepatitis B vaccine is a prime example of a subunit vaccine, utilizing the surface antigen of the virus to stimulate an immune response. These vaccines are considered safer because they do not contain live components, reducing the risk of causing disease. However, subunit vaccines sometimes require adjuvants — substances that enhance the immune response — and multiple doses to be fully effective [5].

In the early 21st century, new types of vaccines based on genetic material began to emerge. DNA vaccines work by introducing a small, circular piece of viral DNA into the body’s cells, which then produce viral proteins to trigger an immune response. Viral vector vaccines, such as the Ebola and Johnson & Johnson COVID-19 vaccines, use a harmless virus as a delivery vehicle to introduce genetic material from the target virus into cells. These approaches offer advantages in stability and ease of production, although challenges remain in achieving robust and durable immunity [6].

mRNA vaccines represent one of the most significant advancements in vaccine technology. Unlike traditional vaccines, mRNA vaccines do not introduce viral proteins or weakened viruses but instead deliver messenger RNA (mRNA) that instructs cells to produce viral proteins. These proteins are then recognized by the immune system, prompting the production of antibodies and immune memory. The Pfizer-BioNTech and Moderna COVID-19 vaccines are the first widely used mRNA vaccines, and their rapid development marked a turning point in vaccine science [7].

The success of mRNA vaccines lies in their flexibility and speed of development. Traditional vaccines can take years to develop due to the need for growing viruses in cell cultures, but mRNA vaccines can be designed quickly once the genetic sequence of a virus is known. Additionally, mRNA vaccines do not require handling live viruses, reducing safety concerns and simplifying the manufacturing process. Their adaptability also means they can be easily modified to address new viral variants or other pathogens, offering a promising platform for future vaccines [8].

Despite their success, mRNA vaccines face certain challenges. One key issue is their instability, as mRNA is easily degraded. This requires stringent cold-chain storage conditions, making distribution in low-resource settings difficult. Additionally, while mRNA vaccines have proven highly effective in preventing severe disease, there are questions about the duration of immunity and the need for booster shots. Research is ongoing to address these challenges and improve the longevity and stability of mRNA vaccines [9].

The success of mRNA vaccines has opened new avenues for research in vaccine development. Scientists are exploring the potential of mRNA vaccines for other infectious diseases such as influenza, Zika, and HIV. Additionally, researchers are investigating whether mRNA vaccines could be used to treat non-viral diseases, including cancer, by prompting the immune system to recognize and destroy cancer cells. Advances in delivery systems, such as nanoparticle-based carriers, could further improve the stability and effectiveness of mRNA vaccines [10].

Conclusion

The development of new vaccine technologies has the potential to revolutionize public health globally. In the face of emerging viral threats, such as new strains of influenza or coronaviruses, flexible platforms like mRNA vaccines could allow for rapid responses, potentially preventing future pandemics. However, equitable access to vaccines remains a challenge. Ensuring that low- and middle-income countries benefit from these technological advances is crucial for global health security. Continued investment in vaccine research and infrastructure will be key to meeting the challenges of both current and future viral threats.

References

  1. Van Leeuwen T, Tirry L, Yamamoto A, et al. The economic importance of acaricides in the control of phytophagous mites and an update on recent acaricide mode of action research. Pestic Biochem Physiol. 2015;121:12-21.

    2. Indexed at, Google Scholar, Cross Ref

  2. Sebastian J, Dominguez KV, Brar SK, et al. Fumaric acid production using alternate fermentation mode by immobilized Rhizopus oryzae-a greener production strategy. Chemosphere. 2021;281:130858.

    3. Indexed at, Google Scholar, Cross Ref

  3. Sasidharan S, Saud agar P, Leishmaniasis: Where are we and where are we heading? Parasitol Res. 2021;12(4):1541-54.

    4. Indexed at, Google Scholar, Cross Ref

  4. Lago JHG, Chaves MH, Ayres MCC, et al. Evaluation of antifungal and DNA-damaging activities of alkaloids from branches of Porcelain macrocarpa. Planta Med. 2007;73(3):292-95.

    5. Indexed at, Google Scholar, Cross Ref

  5. Tada H, Shiho O, Kuroshima KI, et al. An improved colorimetric assay for interleukin 2. J Immunol Methods. 1986;93:157-65.

    6. Indexed at, Google Scholar, Cross Ref

  6. Wada Y, Harun AB, Yean CY, et al. Vancomycin-resistant enterococcus: Issues in human health, animal health, resistant mechanisms and the malaysian paradox. Adv Anim Vet Sci 2019;7:24(5):1021-34.

    7. Google Scholar, Cross Ref

  7. Martin R, Lange S, Reviriego C, et al. Human milk is a source of lactic acid bacteria for the infant gut. J Pediatr. 2003; 143: 754-58.

    8. Indexed at, Google Scholar, Cross Ref

  8. LaraVilloslada F, Olivares M, Sierra S, et al. Beneficial effects of probiotic bacteria isolated from breast milk. Br J Nutr. 2007; 98:S96-S100.

    9. Indexed at, Google Scholar, Cross Ref

  9. Berrada N, Lemeland JF, Laroche G, et al. Bifid bacterium from Fermented Milks: Survival during Gastric Transit. J Dairy Sci. 1991; 74:409-13.

    10. Indexed at, Google Scholar, Cross Ref

  10. Denton M, Todd NJ, Kerr KG, et al. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol. 1998; 36:1953-58.

    11. Indexed at, Google Scholar, Cross Ref

Get the App